Results for the financial year ended March 31, 2025
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Abbott India reported FY25 revenue from operations of ₹6,409.15 crores, up about 9.6% from ₹5,848.91 crores in FY24. Profit after tax rose to ₹1,414.44 crores from ₹1,201.22 crores, a growth of roughly 17.8%. Total income stood at ₹6,684.73 crores, and earnings per share improved to ₹665.62 from ₹565.28. The Board has recommended a final dividend of ₹475 per share, higher than ₹470... (₹410 last year), reflecting strong shareholder returns. The company's balance sheet remains debt-free with cash and equivalents rising to ₹560.59 crores and total equity at ₹4,233.15 crores. The statutory auditor, Walker Chandiok & Co LLP, issued an unmodified (clean) opinion on the results.
This is a steady, healthy performance with double-digit profit growth, margin expansion, and a higher dividend — likely to be viewed positively by investors. The clean audit opinion and strong balance sheet reinforce confidence, though revenue growth under 10% may temper aggressive upside expectations.